

# Institutional Presentation

1Q24



### Disclaimer



The material that follows is a presentation of general background information about Raia Drogasil S.A. (the "Company") as of the date of the presentation. It is information in summary form and does not purport to be complete. It is not intended to be relied upon as advice to potential investors. This presentation is strictly confidential and may not be disclosed to any other person. No representation or warranty, express or implied, is made concerning, and no reliance should be placed on, the accuracy, fairness, or completeness of the information presented herein.

This presentation contains statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Exchange Act of 1934. Such forward-looking statements are only predictions and are not guarantees of future performance. Investors are cautioned that any such forward-looking statements are and will be, as the case may be, subject to many risks, uncertainties and factors relating to the operations and business environments of the Company that may cause the actual results of the companies to be materially different from any future results expressed or implied in such forward-looking statements.

Although the Company believes that the expectations and assumptions reflected in the forward-looking statements are reasonable based on information currently available to the Company's management, the Company cannot guarantee future results or events. The Company expressly disclaims a duty to update any of the forward looking-statements.

Our securities have not been and will not be registered under the Securities Act or under any state securities laws in the United States, and are being offered under exemptions from registration under the Securities Act. Securities may not be offered or sold in the United States unless they are registered or exempt from registration under the Securities Act. Any offering to be made in the United States will be made by means of an offering circular that may be obtained from the agents.

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

## RD Saúde snapshot: Leading the pharma retailing industry in Brazil.



**Our Purpose**: Together for a **healthier society**.

### **Our Ambition**:

To become, by 2030, the group that contributes the most towards a **healthier society** in Brazil.



## +200 years

of combined history of Raia and Drogasil, merged in 2011



**3,010** pharmacies across every Brazilian state



# **48.2** million unique active

unique active customers (1Q24)



**373** million tickets (1Q24 LTM)

R\$ 37.6 billion gross revenue (1Q24 LTM) +16% Y/Y growth



R\$ 2.7 billion adj. EBITDA (1Q24 LTM) +12% Y/Y growth 

## **#1** pharmacy

chain in Brazil in both revenue and pharmacy count



280-300

new pharmacies per year in 2024-2025 (guidance)

	NPS
$(\mathcal{A})$	net promoter
	score

90 pharmacies68 apps







**16.2%** market share (1Q24)



### A decade of consistent high growth in pharmacy count, gross revenue and adj. EBITDA.



# Demand growth due to the ageing of the population. Fragmented market offers ample opportunity for consolidation.







■ RD ■ Abrafarma #2 to 5 ■ Other Chains ■ Assoc./Franch. ■ Independents





(RD Saúde = 100 index. Source: IQVIA.)




# We continue to expand nationwide with unique pace and diversification while sustaining real IRRs above 20% net of cannibalization.










Our Health and Wellness strategy is focused on the **Customer journey**, offering a pharmacy connected to a service platform, positioned in primary care.




Our customers are our greatest asset. In-store experience has increased customer engagement while digitalization has driven more loyalty and frequency, resulting in an increased CLTV.








Our digital and health strategy aims to build bonds with each customer to enhance Customer Annual Value (CAV) according to their profile.




\* Data for 1Q24.




Digital sales of R\$ 1.5 bi in the 1Q24, with 46.4% of growth and <mark>17.3% of retail penetration</mark>. 70% via apps and 92% delivered or collected within 60 minutes.






### Our Health Hubs are improving engagement and customer frequency driving a higher CLTV.









1Q24<br/>NPSPharmacies<br/>90Services<br/>93

RD Ads is a **benchmark in Consumer Health Media**, positively impacting costumers' health, well being and purchasing power, boosting engagement and monetization and LTV.



#### RD Ads revenue breakdown\*



\* 1024

#### The best customers and experience:

- 48.2 million customers;
- 97% sales identification;
- 373 million transactions.

#### **Physical and digital presence:**

- **587** cities;
- 3.0 thousand pharmacies;
- 1.5km distant from 93% of the A-class pop.;
  - **5km** away from 59% of the population;
- Top 10 digital channel (retail audience in Brazil).

#### **Increased relevance with partners:**


- **~500** 1P suppliers;
- 25 of the Top 50 advertisers in Brazil;
- Domain of Category Management and purchase behavior.




Our digital transformation is the result of a profound change in culture, governance, management, operations and in our IT infrastructure.


DIGITALIZATION OF THE CUSTOMER RELATIONSHIP	<ul> <li>17.3% of retail penetration through digital channels;</li> <li>94% of digital sales done through modern and proprietary channels;</li> <li>+25-28% increase in customer spending post-digitalization;</li> <li>Marketplace with 168 thousand SKUs from 736 sellers.</li> </ul>
DIGITAL CULTURE	<ul> <li>Investments in 10 health techs and retail techs through RD Saúde Ventures;</li> <li>Digital and agile mindset.</li> </ul>
GOVERNANCE & MANAGEMENT	<ul> <li>Board with complementary skills: founding families, 5 independents (45%) and 3 women (27%), expertise in pharmaceutical retail, digital transformation, platforms, healthcare and advertising;</li> <li>Seasoned C-Level with 7 members averaging 18 years at RD Saúde;</li> <li>42 executive and corporate directors, of which 25 are occupied by seasoned professionals that joine RD Saúde over the last 5 years, including 20 new positions created during this period.</li> </ul>
DIGITAL PRODUCTS & SOLUTIONS	<ul> <li>Creation of 34 squads and 10 performance desks to support digital products with focus on CI/CX/U&gt;</li> <li>Steady increase in weekly app releases (4x);</li> <li>Creation of a unified data lake and a Data Science area.</li> </ul>
IT INFRASTRUCTURE	<ul> <li>Conversion of core systems to microservices;</li> <li>IT architecture moved from on-premise to the Cloud;</li> <li>Information security and data protection.</li> </ul>

#### Our leading position in the industry allowed us to boost our IT investments by 8x in 5 years to support our Digital Transformation.





The digitalization of the company delivered an increase in our mature store growth and contribution margin, financing the required G&A investments.



# Together with our Business Strategy comes our **Sustainability journey** towards the goals established for 2030.



• Part of **IDIVERSA** B3;

•

- Ranked Top 3 out of 75 companies;
- Launched in Aug/23, highlighting companies that stand out in terms of diversity.



- GPTW<sup>®</sup> certification;
- Sample survey by GPTW® with 5k employees.



- ISO/IEC 27001:2022 Certification (BSI);
- Information Security Certification on Digital Channels (App and Website) and Univers PBM.